Arcutis Biotherapeutics (ARQT)
(Delayed Data from NSDQ)
$10.62 USD
-0.11 (-1.03%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $10.60 -0.02 (-0.19%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ARQT 10.62 -0.11(-1.03%)
Will ARQT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ARQT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARQT
Kazia Therapeutics (KZIA) Soars 490% in a Week: Here's Why
Pacira (PCRX) Rises on Proposed Exparel Reimbursement Plan
ARQT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Inovio (INO) Up as Lead Drug Gets Innovative Medicine Tag in UK
United Therapeutics (UTHR) Completes Enrolment in IPF Study
Indivior (INDV) Down on Dropping Schizophrenia Drug, Cuts '24 View
Other News for ARQT
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age
Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Have $5-10? 7 Affordable Stocks That Are About to Breakout.